Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial

Cold agglutinin disease (CAD) is a complement-dependent disorder, with extravascular and intravascular hemolysis resulting from initial or terminal complement activation, respectively. We tested the efficacy and safety of eculizumab, an inhibitor of the terminal complement pathway. Treatment-requiri...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Adv
Main Authors: Röth, Alexander, Bommer, Martin, Hüttmann, Andreas, Herich-Terhürne, Dörte, Kuklik, Nils, Rekowski, Jan, Lenz, Veronika, Schrezenmeier, Hubert, Dührsen, Ulrich
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2018
Fag:
Transfusion Medicine
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6177646/
https://ncbi.nlm.nih.gov/pubmed/30291112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018024190
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker